Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma

NCT06983210 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma Bladder
Urothelial Carcinoma of the Renal Pelvis and Ureter
Urothelial Carcinoma Urethra
Urothelial Carcinoma Recurrent

Interventions

DRUG: Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy

Sponsor

Nagoya University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]